Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Q1 Revenues and Losses Decrease

NEW YORK, May 15 - Lynx reported somewhat reduced first-quarter revenues today, amid an incremental increase in net losses.


The company, which has recently renewed contracts for its MPSS technology with the Institute for Systems Biology in Seattle and Millennium therapeutics, had revenues of $3.3 million for the quarter, compared to $5.0 million for the previous year's quarter. The company's losses totaled $4.0 million, compared to $3.8 million for the first quarter of last year.


Meanwhile, Lynx's R&D expenses decreased sharply year-over-year, to $3.6 million from $6.9 million for the first quarter of last year.


At the end of March, Lynx had $7.4 million in cash and cash equivalents, compared to $11.7 million at the end of December, 2002.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.